RG
SLXP

Redmile Group’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Redmile Group’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-3,300
Closed -$218K – 69
2013
Q2 		$218K Buy
+3,300
New +$189K 0.04% 45

Other funds holding SLXP

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Redmile Group's SLXP Position: Q3 2013 in Review

Redmile Group sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q3 2013, closing a stake of 3,300 shares — an estimated $218K sold.

Redmile Group first reported a position in SLXP in Q2 2013 and held it in 1 quarter. The position peaked at $218K in Q2 2013. 251 funds tracked by Wall St. Rank hold SLXP as of Q3 2013.

  • Redmile Group reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q3 2013 after selling out during the quarter.
  • Redmile Group sold 3,300 SALIX PHARMACEUTICALS LTD DEL shares in Q3 2013, an estimated $218K.
  • Redmile Group first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 1 quarter.
  • Redmile Group's SALIX PHARMACEUTICALS LTD DEL position peaked at $218K in Q2 2013.
  • 251 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q3 2013.

Based on Redmile Group's 13F filing for Q3 2013, filed 14 Nov 2013.